Increased levels of Arginase in patients with acute hepatitis B suppress antiviral T cells Sandalova E, Laccabue D, Boni C, Watanabe T, Tan A, Zong HZ, Ferrari C, Bertoletti A. Gastroenterology. 2012 Apr 1. [Epub ahead of print]
	Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. PLoS One. 2012;7(3):e34198. Epub 2012 Mar 30.
	High Rates of Viral Suppression After Long-Term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. Clin Gastroenterol Hepatol. 2012 Apr 1. [Epub ahead of print]
	Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure Yang WB, Chen EQ, Bi HX, Bai L, Chen XB, Feng P, Tang H. Ann Hepatol. 2012 May;11(3):311-9.
	Saliva as a tool in the detection of hepatitis B surface antigen in patients Arora G, Sheikh S, Pallagatti S, Singh B, Singh VA, Singh R. Compend Contin Educ Dent. 2012 Mar;33(3):174-6, 178; quiz 180, 182.
	Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression? Wu Q, Liu Q. Hepatol Res. 2012 Mar 2. doi: 10.1111/j.1872-034X.2012.00994.x. [Epub ahead of print]
	Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression? Wu Q, Liu Q. Hepatol Res. 2012 Mar 2. doi: 10.1111/j.1872-034X.2012.00994.x. [Epub ahead of print]
	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Aliment Pharmacol Ther. 2012 Apr 16. doi: 10.1111/j.1365-2036.2012.05098.x. [Epub ahead of print]
	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL; for the VIRGIL Surveillance Study Group. Gut. 2012 Apr 5. [Epub ahead of print]
	Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? Altinbas A, Aktas B, Basar O, Yüksel O, Ekiz F, Yilmaz B, Coban S. Ann Hepatol. 2012 May;11(3):320-5.
	Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection Li N, Gao YF, Zhang TC, Chen P, Li X, Su F. World J Hepatol. 2012 Mar 27;4(3):105-9.
	Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Aliment Pharmacol Ther. 2012 Apr 16. doi: 10.1111/j.1365-2036.2012.05093.x. [Epub ahead of print]
	Similar Risk of Renal Events Among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Clin Gastroenterol Hepatol. 2012 Apr 13. [Epub ahead of print]
	Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? Iloeje UH, Yang HI, Chen CJ. Liver Int. 2012 Apr 17. doi: 10.1111/j.1478-3231.2012.02805.x. [Epub ahead of print]
	New advances in chronic hepatitis B Tujios SR, Lee WM. Curr Opin Gastroenterol. 2012 Mar 23. [Epub ahead of print]
	Undertreatment of Asian Chronic Hepatitis B Patients on the Basis of Standard Guidelines: A Community-Based Study Zhang S, Ristau JT, Trinh HN, Garcia RT, Nguyen HA, Nguyen MH. Dig Dis Sci. 2012 Mar 31. [Epub ahead of print]
	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Aliment Pharmacol Ther. 2012 Mar 26. doi: 10.1111/j.1365-2036.2012.05059.x. [Epub ahead of print]
	Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Liver Int. 2012 Mar 27. doi: 10.1111/j.1478-3231.2012.02793.x. [Epub ahead of print]
	Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. J Hepatol. 2012 Mar 23. [Epub ahead of print]
	IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2012 Apr 2. doi: 10.1002/hep.25749. [Epub ahead of print]
	Patients with hematological malignancies and serological signs of prior resolved hepatitis B Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. World J Gastrointest Oncol. 2012 Mar 15;4(3):37-45.
	Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs Novellino L, Rossi RL, Bonino F, Cavallone D, Abrignani S, Pagani M, Brunetto MR. PLoS One. 2012;7(3):e31952. Epub 2012 Mar 28.
	Hepatitis B serology Towell V, Cowie B. Aust Fam Physician. 2012 Apr;41(4):212-4.
	Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis Wan S, Hann HW, Myers RE, Fu X, Hann RS, Kim SH, Tang H, Xing J, Yang H. Liver Int. 2012 Apr 4. doi: 10.1111/j.1478-3231.2012.02801.x. [Epub ahead of print]
	Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a U.S. recommendation for vaccination Byrd KK, Lu PJ, Murphy TV. Vaccine. 2012 Mar 31. [Epub ahead of print]
	Improved Efficacy by Individualized Combination Therapy with Peg IFN-a 2a and ADV in HBeAg Positive Chronic Hepatitis B Patients Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ. Hepatogastroenterology. 2012 Mar 20;59(115). doi: 10.5754/hge12183. [Epub ahead of print]
	Transient elastography and simple blood markers in diagnosis of oesophageal varices for compensated patients with hepatitis B virus-related cirrhosis Wang JH, Chuah SK, Lu SN, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. J Gastroenterol Hepatol. 2012 Mar 20. doi: 10.1111/j.1440-1746.2012.07132.x. [Epub ahead of print]
	High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH. Eur J Cancer Prev. 2012 May;21(3):261-7.
	Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires Giang L, Selinger CP, Lee AU. World J Hepatol. 2012 Feb 27;4(2):43-9.
	A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. Hepatology. 2012 Mar 15. doi: 10.1002/hep.25718. [Epub ahead of print]
	Prevention of de novo hepatitis B with adefovir dipivoxil (ADV) in recipients of liver grafts from hepatitis B core antibody positive (HBcAb+) donors Chang MS, Olsen SK, Pichardo EM, Heese S, Stiles JB, Abdelmessih R, Verna EC, Guarrera JV, Emond JC, Brown RS. Liver Transpl. 2012 Mar 16. doi: 10.1002/lt.23429. [Epub ahead of print]
	Model for End-stage Liver Disease and Model for End-stage Liver Disease-Na Scores Predict Both Before-Listing and Wait-List Mortality Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Nojiri K, Aoki T, Sakamoto Y, Hasegawa K, Koike K, Kokudo N. Transplant Proc. 2012 Mar;44(2):389-92.
	Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak Williams RE, Sena AC, Moorman AC, Moore ZS, Sharapov UM, Drobenuic J, Hu DJ, Wood HW, Xing J, Spradling PR. Vaccine. 2012 Mar 12. [Epub ahead of print]
	The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A. Am J Blood Res. 2012;2(1):18-28. Epub 2012 Jan 1.
	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. PLoS One. 2012;7(2):e32622. Epub 2012 Feb 28.
	Analysis of Precore/Core Covariances Associated with Viral Kinetics and Genotypes in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients Cheng CP, Lee PF, Liu WC, Wu IC, Chin CY, Chang TT, Tseng VS. PLoS One. 2012;7(2):e32553. Epub 2012 Feb 27
	Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation Kim SU, Kim JK, Park YN, Han KH. PLoS One. 2012;7(2):e32233. Epub 2012 Feb 23.
	Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients Buti M, Morillas RM, Prietoj M, Diago M, Pérez J, Solà R, Bonet L, Palauj A, Testillano M, García-Samaniego J, Rodríguez M; the ORIENTE Study Group. Eur J Gastroenterol Hepatol. 2012 Feb 29. [Epub ahead of print]
	Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis Zheng XY, Wei RB, Tang L, Li P, Zheng XD. World J Gastroenterol. 2012 Feb 28;18(8):821-32.
	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection Matsumoto A, Tanaka E, Morita S, Yoshizawa K, Umemura T, Joshita S. J Gastroenterol. 2012 Feb 29. [Epub ahead of print]
	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Gastroenterol. 2012 Feb 29. [Epub ahead of print]
	Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy Dupouey J, Gerolami R, Solas C, Colson P. Clin Res Hepatol Gastroenterol. 2012 Feb 17. [Epub ahead of print]
	Hepatitis B Infection in the Asian and Latino Communities of Alameda County, California Hur K, Wong M, Lee J, Lee J, Juon HS. J Community Health. 2012 Feb 24. [Epub ahead of print]
	Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication Hodgson AA, Hyser JM, Keasler VV, Cang Y, Slagle BL. Virology. 2012 Feb 16. [Epub ahead of print]
	Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY. Braz J Infect Dis. 2012 Feb;16(1):9-14.
	Neuromuscular disorders associated with hepatitis B virus infection Stübgen JP. J Clin Neuromuscul Dis. 2011 Sep;13(1):26-37.
	Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF? agents: A retrospective analysis of 49 cases Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH, Kim SI, Lee EB, Song YW. Clin Rheumatol. 2012 Feb 17. [Epub ahead of print]
	Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation Todd Stravitz R, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, Fisher RA. Liver Int. 2012 Feb 21. doi: 10.1111/j.1478-3231.2012.02770.x. [Epub ahead of print]
	The role of adherence in virological suppression in patients receiving anti-HBV analogues Sogni P, Carrieri MP, Fontaine H, Mallet V, Vallet-Pichard A, Trabut JB, Méritet JF, Pol S. Antivir Ther. 2011 Nov 3. doi: 10.3851/IMP1944. [Epub ahead of print]
	Viral Hepatitis in the Elderly Carrion AF, Martin P. Am J Gastroenterol. 2012 Jan 31. doi: 10.1038/ajg.2012.7. [Epub ahead of print]
	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. J Med Virol. 2012 Mar;84(3):424-30. doi: 10.1002/jmv.23229.
	Hepatitis B infection: current concepts and future challenges Nebbia G, Peppa D, Maini MK. QJM. 2012 Feb;105(2):109-13.
	Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW. Scand J Gastroenterol. 2012 Jan 23. [Epub ahead of print]
	Downgrading MELD Improves the Outcomes after Liver Transplantation in Patients with Acute-on-Chronic Hepatitis B Liver Failure Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, Chen J, Xia Q, Xie H, Wu J, Zheng S, Li L. PLoS One. 2012;7(1):e30322. Epub 2012 Jan 24.
	Estimating the Prevalence of Chronic Hepatitis B Virus Infection-New York City, 2008 France AM, Bornschlegel K, Lazaroff J, Kennedy J, Balter S. J Urban Health. 2012 Jan 13. [Epub ahead of print]
	Adult vaccination coverage - United States, 2010 Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61:66-72.
	Can we direct organ allocation based on predicted outcome? Hepatocellular carcinoma outside of UCSF criteria or retransplant? Rochon C, Sheiner P, Mahadevappa B, Gunasekaran G, Sharma J, Wolf DC, Facciuto M. Langenbecks Arch Surg. 2012 Jan 28. [Epub ahead of print]
	Interventional Radiologic Treatment of Hepatocellular Carcinoma-A Cost Analysis from the Payer Perspective Ray CE Jr, Battaglia C, Libby AM, Prochazka A, Xu S, Funaki B. J Vasc Interv Radiol. 2012 Jan 23. [Epub ahead of print]
	Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation Hsu YC, Mo LR, Chang CY, Perng DS, Tseng CH, Lo GH, Tai CM, Lin CW, Hsu CC, Hsu CY, Huang SC, Lin JT. Antivir Ther. 2011 Dec 20. doi: 10.3851/IMP2027. [Epub ahead of print]
	Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis B Wang J, Cai Y, Ji H, Feng J, Ayana DA, Niu J, Jiang Y. J Interferon Cytokine Res. 2012 Feb 3. [Epub ahead of print]
	Hepatitis B virus in transfusion medicine: Still a problem? Allain JP, Candotti D; the ISBT HBV Safety Collaborative Group. Biologicals. 2012 Feb 1. [Epub ahead of print]
	The current economic burden of cirrhosis Neff GW, Duncan CW, Schiff ER. Gastroenterol Hepatol (N Y). 2011 Oct;7(10):661-71.
	Correlation of improved hepatitis?B surface antigen detection limits with hepatitis?B virus DNA nucleic acid test yield in blood donations Martin LA, Stramer SL, Kuhns MC, Schlauder GG. Transfusion. 2012 Feb 10. doi: 10.1111/j.1537-2995.2011.03553.x. [Epub ahead of print]
	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements Jang HW, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Park YN, Choi EH, Kim do Y. Yonsei Med J. 2012 Mar 1;53(2):337-45. doi: 10.3349/ymj.2012.53.2.337.
	Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N, Lee DH. Korean J Hepatol. 2011 Dec;17(4):268-73. doi: 10.3350/kjhep.2011.17.4.268.
	Does Interleukin-28B (IL-28B) single nucleotide polymorphisms influence the natural history of hepatitis B? Martin-Carbonero L, Rallón N, Benito JM, Poveda E, González-Lahoz J, Soriano V. AIDS Res Hum Retroviruses. 2012 Feb 12. [Epub ahead of print]
	Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, Chen X, Wei L. Cancer Immunol Immunother. 2012 Feb 4. [Epub ahead of print]
	Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants Billioud G, Pichoud C, Parent R, Zoulim F. J Hepatol. 2012 Feb 4. [Epub ahead of print]
	Napa Immunization Study: Immunization Rates for Children with Publicly Funded Insurance Compared with those with Private Health Insurance in a Suburban Medical Office Cotter JC. Perm J. 2011 Fall;15(4):12-22.
	Safety and efficacy of two-step peginterferon ?-2a treatment in patients of chronic hepatitis B with acute exacerbation Chen CC, Wang PC, Chang HW, Chen CF. J Viral Hepat. 2012 Mar;19(3):161-72. doi: 10.1111/j.1365-2893.2011.01469.x. Epub 2011 Jul 4.
	Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. J Viral Hepat. 2012 Mar;19(3):205-12. doi: 10.1111/j.1365-2893.2011.01494.x. Epub 2011 Jul 14.
	Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area Kang HY, Shin HD, Kim SB, Song IH. Clin Res Hepatol Gastroenterol. 2012 Feb 8. [Epub ahead of print]
	Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L. Int J Immunogenet. 2012 Feb 10. doi: 10.1111/j.1744-313X.2012.01097.x. [Epub ahead of print]
	Quality of Life and the Relevant Factors in Patients with Chronic Hepatitis B Wang L, Wang Y, Tang L, Feng C, Liu X, Zhang R, Liu D. Hepatogastroenterology. 2012 Feb 10;59(116). doi: 10.5754/hge11867. [Epub ahead of print]
	Selection of chronic hepatitis B therapy with high barrier to resistance Gish R, Jia JD, Locarnini S, Zoulim F. Lancet Infect Dis. 2012 Feb 8. [Epub ahead of print]
	Peginteferon-? does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M, Colombo M, Loggi E, Missale G, Ferrari C. J Hepatol. 2012 Feb 9. [Epub ahead of print]
	Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17.
	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, Martz R, Meyer I, McNeil S, Langley JM, Martins E, Heyward WL, Martin JT. Vaccine. 2012 Feb 8. [Epub ahead of print]
	Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K. AIDS. 2012 Feb 13. [Epub ahead of print]
	Antiviral therapy of decompensated hepatitis B virus-related cirrhosis Chen GC, Yu T, Huang KH, Chen QK. Chin Med J (Engl). 2012 Jan;125(2):373-7.
	Consumption of n-3 Fatty Acids and Fish Reduces Risk of Hepatocellular Carcinoma Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takashi R, Tanaka Y, Mizokami M, Tsugane S; Japan Public Health Center-based Prospective StudyGroup.. Gastroenterology. 2012 Feb 16. [Epub ahead of print]
	Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. J Viral Hepat. 2012 Mar;19(3):220-6. doi: 10.1111/j.1365-2893.2011.01542.x. Epub 2011 Oct 19.
	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients with Low HBV Load Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Gastroenterology. 2012 Feb 11. [Epub ahead of print]
	Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B Huang Z, van Velkinburgh JC, Ni B, Wu Y. Liver Int. 2012 Feb 19. doi: 10.1111/j.1478-3231.2012.02764.x. [Epub ahead of print]
	Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B Huang Z, van Velkinburgh JC, Ni B, Wu Y. Liver Int. 2012 Feb 19. doi: 10.1111/j.1478-3231.2012.02764.x. [Epub ahead of print]
	Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. BMC Gastroenterol. 2012 Feb 14;12(1):14. [Epub ahead of print]
	Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B Chen Y, Ju T. Int J Infect Dis. 2012 Jan 4. [Epub ahead of print]
	Viral infections and human cancers: the legacy of Denis Burkitt Harford JB. Br J Haematol. 2012 Jan 11. doi: 10.1111/j.1365-2141.2011.09017.x. [Epub ahead of print]
	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901 Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Expert Opin Drug Saf. 2012 Jan 11. [Epub ahead of print]
	Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Peng CY, Lai HC, Li YF, Su WP, Chuang PH, Kao JT. Aliment Pharmacol Ther. 2012 Feb;35(4):458-68. doi: 10.1111/j.1365-2036.2011.04973.x. Epub 2012 Jan 8.
	Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. J Gastroenterol. 2012 Jan 11. [Epub ahead of print]
	"Never Events": Hepatitis B Outbreaks and Patient Notifications Resulting from Unsafe Practices during Assisted Monitoring of Blood Glucose, 2009-2010 Thompson ND, Schaefer MK. J Diabetes Sci Technol. 2011 Nov 1;5(6):1396-402.
	Efficacy of Lamivudine or entecavir on acute exacerbation of chronic hepatitis B Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, Fujiwara K, Goto N, Imazeki F, Yokosuka O. Int J Med Sci. 2012;9(1):27-32. Epub 2011 Nov 10.
	Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B Chen Y, Ju T. Int J Infect Dis. 2012 Jan 4. [Epub ahead of print]
	Do prior contraceptive methods impact maternal carriage in patients with hepatitis B? Lao TT, Chan OK, Suen SS, Leung TY. Hepat Mon. 2011 Oct 1;11(10):829-34.
	Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies Sayan M, Akhan SC, Senturk O. Hepat Mon. 2011 Oct 1;11(10):835-42.
	ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, Yang X, Fan WB, Gai ZT, Chen SJ, Kato N. PLoS One. 2012;7(1):e29928. Epub 2012 Jan 3.
	Adefovir dipivoxil in chronic hepatitis B: history and current uses Segovia MC, Chacra W, Gordon SC. Expert Opin Pharmacother. 2012 Feb;13(2):245-54.
	Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ. Antivir Ther. 2012;17(1):53-60.
	Serial HBV DNA levels in patients with persistently normal transaminase over 10?years following spontaneous HBeAg seroconversion Chen YC, Huang SF, Chu CM, Liaw YF. J Viral Hepat. 2012 Feb;19(2):138-46. doi: 10.1111/j.1365-2893.2011.01450.x. Epub 2011 Mar 14.
	Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY. J Viral Hepat. 2012 Feb;19(2):e41-7. doi: 10.1111/j.1365-2893.2011.01509.x. Epub 2011 Nov 20.
	The Option of HBIG-Free Prophylaxis Against Recurrent HBV Fox AN, Terrault NA. J Hepatol. 2012 Jan 21. [Epub ahead of print]
	Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance Arai M, Togo S, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Eur J Gastroenterol Hepatol. 2012 Jan 23. [Epub ahead of print]
	Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity Ott JJ, Stevens GA, Groeger J, Wiersma ST. Vaccine. 2012 Jan 21. [Epub ahead of print]
	High Hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study Zhou JY, Zhang L, Li L, Gu GY, Zhou YH, Chen JH. Virol J. 2012 Jan 13;9(1):16. [Epub ahead of print]
	IL28B rs12979860 polymorphism dose not influence outcomes of hepatitis B virus infection Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. Tissue Antigens. 2012 Jan 13. doi: 10.1111/j.1399-0039.2011.01835.x. [Epub ahead of print]
	Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis Singal AK, Fontana RJ. Aliment Pharmacol Ther. 2012 Jan 19. doi: 10.1111/j.1365-2036.2011.04990.x. [Epub ahead of print]
	Surveillance for chronic hepatitis B virus infection - new york city, june 2008-november 2009 Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 Jan 13;61:6-9.
	Validation of A Stopping Rule at Week 12 Using HBsAg and HBV DNA for HBeAg-Negative Patients Treated with Peginterferon Alfa-2a Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Galeota Lanza A, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P. J Hepatol. 2012 Jan 12. [Epub ahead of print]
	Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-?2b: relation to response and HBV genotype Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL. Antivir Ther. 2012;17(1):9-17.
	Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer Torres HA, Davila M. Nat Rev Clin Oncol. 2012 Jan 24. doi: 10.1038/nrclinonc.2012.1. [Epub ahead of print]
	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Ann Hematol. 2012 Jan 25. [Epub ahead of print]
	Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection Tsan YT, Lee CH, Wang JD, Chen PC. J Clin Oncol. 2012 Jan 23. [Epub ahead of print]
	Hepatitis B in the United States: ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007 Ladak F, Gjelsvik A, Feller E, Rosenthal S, Montague BT. Infection. 2012 Jan 12. [Epub ahead of print]
	Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. Gut Liver. 2011 Dec;5(4):478-85. Epub 2011 Nov 21.
	Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM; The Acute Liver Failure Study Group. Dig Dis Sci. 2011 Dec 25. [Epub ahead of print]
	Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients Kim KM, Eo SJ, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Gut Liver. 2011 Dec;5(4):500-5. Epub 2011 Nov 21.
	A systematic review of the fetal safety of interferon alpha Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. Reprod Toxicol. 2011 Dec 19. [Epub ahead of print]
	Effects of Maternal Screening and Universal Immunization to Prevent Mother-To-Infant Transmission of HBV Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY, Chang MH. Gastroenterology. 2011 Dec 22. [Epub ahead of print]
	Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B Jiang X, Zhang M, Lai Q, Huang X, Li Y, Sun J, Abbott WG, Ma S, Hou J. PLoS One. 2011;6(12):e28871. Epub 2011 Dec 16.
	Emerging pipeline drugs for hepatitis B infection Cox N, Tillmann H. Expert Opin Emerg Drugs. 2011 Dec;16(4):713-29.
	Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60:1709-11.
	Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases Wang K, Zhu ZJ, Zheng H, Deng YL, Pan C, Sun LY, Shen ZY. Hepatol Res. 2011 Dec 16. doi: 10.1111/j.1872-034X.2011.00926.x. [Epub ahead of print]
	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Expert Opin Biol Ther. 2011 Dec 22. [Epub ahead of print]
	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Digestion. 2011;84 Suppl 1:23-8. Epub 2011 Dec 2.
	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma Izumi N. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00922.x. [Epub ahead of print]
	Treatment of chronic hepatitis B with nucleos(t)ide analogues Ohishi W, Chayama K. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00921.x. [Epub ahead of print]
	Hepatitis B virus serology to predict antiviral response in chronic hepatitis B Kim BK, Han KH, Ahn SH. Digestion. 2011;84 Suppl 1:29-34. Epub 2011 Dec 2.
	The increasing burden of imported chronic hepatitis B - United States, 1974-2008 Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. PLoS One. 2011;6(12):e27717. Epub 2011 Dec 7.
	Hepatitis B virus infection and the risk of hepatocellular carcinoma Tan YJ. World J Gastroenterol. 2011 Nov 28;17(44):4853-7.
	The Efficacy and Tolerability of Pegylated Interferon-?-2a in Chronic Hepatitis B: A Multicenter Clinical Experience Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W. J Gastroenterol Hepatol. 2011 Dec 14. doi: 10.1111/j.1440-1746.2011.07051.x. [Epub ahead of print]
	Efficacy of High-Dose Intra-dermal Hepatitis B Virus Vaccine in Previous Vaccination Non-responders with Chronic Liver Disease Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, Beesla A, Murphy L, Van Thiel DH. Dig Dis Sci. 2011 Dec 9. [Epub ahead of print]
	Recent advances in the management of chronic hepatitis B Kim SR, Yang J, Kudo M, Hino O. Hepat Mon. 2011 Aug 1;11(8):601-11.
	Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease Keating GM. Drugs. 2011 Dec 24;71(18):2511-29. doi: 10.2165/11208510-000000000-00000.
	Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin Ahn J, Cohen SM. Hepat Mon. 2011 Aug 1;11(8):638-45.
	Entecavir Monotherapy is Eeffective in Suppressing Hepatitis B Virus after Liver Transplantation Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Gastroenterology. 2011 Jul 12.
	Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG, Silva MO. Int J Clin Pract. 2011 Aug;65(8):866-870. doi: 10.1111/j.1742-1241.2011.02719.x.
	Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels Cheong JY, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW. Liver Int. 2011 Jun 23. doi: 10.1111/j.1478-3231.2011.02570.x.
	Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age Ray P, Black S, Shinefield H, Dillon A, Carpenter D, Lewis E, Ross P, Chen RT, Klein NP, Baxter R; for the Vaccine Safety Datalink Team. Vaccine. 2011 Jul 13.
	A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang Z, Zhao H, Yan J, Cheng J. Hepatol Int. 2011 Jul 20.
	Frequency and Risk Factors of Renal Impairment During Long-term Adefovir Dipivoxil Treatment in Chronic Hepatitis B Patients Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. J Gastroenterol Hepatol. 2011 Jul 20. doi: 10.1111/j.1440-1746.2011.06852.x.
	Cost effectiveness of screening immigrants for hepatitis B Wong WW, Woo G, Jenny Heathcote E, Krahn M. Liver Int. 2011 Jun 14. doi: 10.1111/j.1478-3231.2011.02559.x.
	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R, Wedemeyer H, Janssen HL, Zoulim F. Antiviral Res. 2011 Jul 15.
	Update on childhood and adolescent immunizations: selected review of US recommendations and literature: part 1 Fay KE, Lai J, Bocchini JA Jr. Curr Opin Pediatr. 2011 Aug;23(4):460-9.
	Hepatitis B Vaccination Coverage and Documented Seroprotection among Matriculating Healthcare Students at an Academic Institution in the United States Tohme RA, Ribner B, Huey MJ, Spradling PR. Infect Control Hosp Epidemiol. 2011 Aug;32(8):818-21.
	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography Ong A, Wong VW, Wong GL, Chan HL. Liver Int. 2011 Aug;31(7):1047-53. doi: 10.1111/j.1478-3231.2011.02555.x. Epub 2011 May 31.
	Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis Shi Y, Wu YH, Wei W, Zhang WJ, Yang J, Chen Z. Liver Int. 2011 Feb 23. doi: 10.1111/j.1478-3231.2011.02481.x.
	Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2?cm in a hepatitis B virus-endemic area Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, Shin YM, Yu ES, Chung YH, Suh DJ. Liver Int. 2011 Apr 11. doi: 10.1111/j.1478-3231.2011.02529.x.
	The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH.
	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Dig Dis Sci. 2011 Jul 9.
	Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation Isaacs D, Kilham HA, Alexander S, Wood N, Buckmaster A, Royle J. Vaccine. 2011 Jun 29.
	Hepatitis B surface antigen Quantification: Why and How to use it in 2011 - A Core Group Report Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P; for the Good Practice in using sAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). J Hepatol. 2011 Jun 27.
	Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something? Chan OK, Lao TT, Suen SS, Lau TK, Leung TY. Infection. 2011 Jun 29.
	Predictive Effect of Serial Serum Alanine Aminotransferase Levels on Spontaneous HBeAg Seroconversion in Chronic Genotypes B and C HBV infected Children Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Wang JL, Chang MH. J Pediatr Gastroenterol Nutr. 2011 Jun 28.
	Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Ann Rheum Dis. 2011 Jun 29.
	Knowledge of Hepatitis B Risk Factors and Prevention Practices among Individuals Chronically Infected with Hepatitis B in San Francisco, California Nishimura A, Shiono P, Stier D, Shallow S, Sanchez M, Huang S. J Community Health. 2011 Jun 30.
	Tenofovir nephrotoxicity: 2011 update Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. AIDS Res Treat. 2011;2011:354908. Epub 2011 Jun 7.
	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the united states population Younossi ZM, Stepanova M. Hepatology. 2011 Jul 2. doi: 10.1002/hep.24510.
	Alcohol Consumption Is Inversely Correlated With Insulin Resistance, Independent of Metabolic Syndrome Factors and Fatty Liver Diseas Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Urabe A. J Clin Gastroenterol. 2011 Jun 20.
	Should chronic hepatitis B mothers breastfeed? A meta analysis Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, Wei S. BMC Public Health. 2011 Jun 27;11(1):502.
	Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.
	Hepatitis B surface antigen monitoring and management of chronic hepatitis B Sonneveld MJ, Zoutendijk R, Janssen HL. J Viral Hepat. 2011 Jul;18(7):449-57. doi: 10.1111/j.1365-2893.2011.01465.x. Epub 2011 May 23.
	Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Int J Cancer. 2011 Sep 1;129(5):1254-64. doi: 10.1002/ijc.25767. Epub 2011 Jan 6.
	A Proinflammatory Role For Interleukin-22 In The Immune Response To Hepatitis B Virus Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD. Gastroenterology. 2011 Jun 24.
	Adefovir serum levels do not differ between responders and nonresponders Deterding K, Naesens L, Buti M, Janssen H, Kirschner J, Guerrero A, Reijnders J, Neyts J, Zoulim F, Wedemeyer H. J Viral Hepat. 2011 Jul;18(7):e175-8. doi: 10.1111/j.1365-2893.2010.01404.x. Epub 2011 Jan 7.
	The clinical implications of hepatitis B virus genotype: Recent advances Lin CL, Kao JH. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:123-30.
	An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, Zheng SQ, Zhao YR, Zhang SL. J Viral Hepat. 2011 Jul;18(7):e184-90. doi: 10.1111/j.1365-2893.2010.01423.x. Epub 2011 Jan 13.
	Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B Zhang NP, Reijnders JG, Perquin M, Hansen BE, Janssen HL. J Viral Hepat. 2011 Jul;18(7):e252-7. doi: 10.1111/j.1365-2893.2011.01448.x. Epub 2011 Mar 1.
	Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S, Khan MQ, Alghamdi AS, Farah T, Al-Hamoudi W, Saadeh M, Abdo AA. J Viral Hepat. 2011 Jul;18(7):e217-e225. doi: 10.1111/j.1365-2893.2011.01437.x. Epub 2011 Mar 1.
	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, Wang H, Lai JY, Chen SJ, Jia JD, Sheng JF, Chan HL, Wang JF, Li MK, Jiang M, Popescu M, Sung JJ. Aliment Pharmacol Ther. 2011 Jun 22. doi: 10.1111/j.1365-2036.2011.04750.x.
	Pregnancy outcomes associated with viral hepatitis Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.
	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. J Viral Hepat. 2011 Jul;18(7):e200-5. doi: 10.1111/j.1365-2893.2010.01428.x. Epub 2011 Jan 7.
	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection Seto WK, Yuen MF, Fung J, Lai CL. Hepatol Int. 2011 Jun 19.
	Drug safety evaluation of adefovir in HBV infection Viganò M, Lampertico P, Colombo M. Expert Opin Drug Saf. 2011 Jun 15.
	Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Curr Hepat Rep. 2011 Jun;10(2):87-97. Epub 2011 Mar 1.
	Hepatitis B virus infection and pregnancy Pol S, Corouge M, Fontaine H. Clin Res Hepatol Gastroenterol. 2011 Jun 7.
	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatol Int. 2011 Jun 14.
	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL. Aliment Pharmacol Ther. 2011 Jun 14. doi: 10.1111/j.1365-2036.2011.04738.x.
	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Gastroenterology. 2011 Apr 28.
	Adverse effects of hepatitis B virus on sperm motility and fertilization ability during IVF Oger P, Yazbeck C, Gervais A, Dorphin B, Gout C, Jacquesson L, Ayel JP, Kahn V, Rougier N. Reprod Biomed Online. 2011 May 12.
	Combination Therapy for Chronic Hepatitis B: Current Indications Paul N, Han SH. Curr Hepat Rep. 2011 Jun;10(2):98-105. Epub 2011 Feb 19.
	Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. BMC Infect Dis. 2011 Jun 9;11(1):165. [
	Treatment of special populations with chronic hepatitis B infection Rapti IN, Hadziyannis SJ. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):323-39.
	Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O. Scand J Gastroenterol. 2011 May 30.
	Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy Kim YM, Jeong SH, Kim JW, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH. J Clin Virol. 2011 May 29.
	Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy Ohishi W, Chayama K. Clin Exp Nephrol. 2011 Jun 1.
	Chronic Liver Disease in the Hispanic Population of the United States Carrion AF, Ghanta R, Carrasquillo O, Martin P. Clin Gastroenterol Hepatol. 2011 May 12.
	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the united states population Younossi ZM, Stepanova M. Hepatology. 2011 Jul 2. doi: 10.1002/hep.24510. [Epub ahead of print]
	Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation Isaacs D, Kilham HA, Alexander S, Wood N, Buckmaster A, Royle J. Vaccine. 2011 Jun 29. [Epub ahead of print]
	Hepatitis B surface antigen Quantification: Why and How to use it in 2011 - A Core Group Report Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P; for the Good Practice in using sAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). J Hepatol. 2011 Jun 27. [Epub ahead of print]
	Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something? Chan OK, Lao TT, Suen SS, Lau TK, Leung TY. Infection. 2011 Jun 29. [Epub ahead of print]
	Predictive Effect of Serial Serum Alanine Aminotransferase Levels on Spontaneous HBeAg Seroconversion in Chronic Genotypes B and C HBV infected Children Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Wang JL, Chang MH. J Pediatr Gastroenterol Nutr. 2011 Jun 28. [Epub ahead of print]
	Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Ann Rheum Dis. 2011 Jun 29. [Epub ahead of print]
	Knowledge of Hepatitis B Risk Factors and Prevention Practices among Individuals Chronically Infected with Hepatitis B in San Francisco, California Nishimura A, Shiono P, Stier D, Shallow S, Sanchez M, Huang S. J Community Health. 2011 Jun 30. [Epub ahead of print]
	Tenofovir nephrotoxicity: 2011 update Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. AIDS Res Treat. 2011;2011:354908. Epub 2011 Jun 7.
	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography Ong A, Wong VW, Wong GL, Chan HL. Liver Int. 2011 Aug;31(7):1047-53. doi: 10.1111/j.1478-3231.2011.02555.x. Epub 2011 May 31.
	Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis Shi Y, Wu YH, Wei W, Zhang WJ, Yang J, Chen Z. Liver Int. 2011 Feb 23. doi: 10.1111/j.1478-3231.2011.02481.x. [Epub ahead of print]
	Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2?cm in a hepatitis B virus-endemic area Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, Shin YM, Yu ES, Chung YH, Suh DJ. Liver Int. 2011 Apr 11. doi: 10.1111/j.1478-3231.2011.02529.x. [Epub ahead of print]
	The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH.
	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Dig Dis Sci. 2011 Jul 9. [Epub ahead of print]
	Antiretroviral use during pregnancy for treatment or prophylaxis Sturt AS, Read JS. Expert Opin Pharmacother. 2011 May 3. [Epub ahead of print]
	Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection Li J, Han Y, Jin K, Wan Y, Wang S, Liu B, Liu Y, Lu S, Huang Z. Virol J. 2011 May 2;8(1):199. [Epub ahead of print]
	The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C Zani C, Pasquale L, Bressanelli M, Puoti M, Paris B, Coccaglio R, Lascioli I, Pieriacci G, Donato F. Dig Liver Dis. 2011 Apr 28. [Epub ahead of print]
	Hepatitis B virus infection from an evolutionary point of view: How viral, host, and environmental factors shape genotypes and subgenotypes Araujo NM, Waizbort R, Kay A. Infect Genet Evol. 2011 Apr 22. [Epub ahead of print]
	Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention Giacomin A, Cazzagon N, Sergio A, Vanin V, Farinati F. Eur J Cancer Prev. 2011 May 2. [Epub ahead of print]
	Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants Köse S, Türken M, Devrim I, Taner C. J Infect Dev Ctries. 2011 Apr 26;5(4):303-6.
	Hepatitis B virus and renal transplantation Kalia H, Fabrizi F, Martin P. Transplant Rev (Orlando). 2011 Apr 27. [Epub ahead of print]
	The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States Eckman MH, Kaiser TE, Sherman KE. Clin Infect Dis. 2011 May 2. [Epub ahead of print]
	Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration Akbar SM, Al-Mahtab M, Hiasa Y. J Gastroenterol. 2011 Apr 28. [Epub ahead of print]
	An overview of occult hepatitis B virus infection Said ZN. World J Gastroenterol. 2011 Apr 21;17(15):1927-38.
	Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mori S. Mod Rheumatol. 2011 Apr 29. [Epub ahead of print]
	Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Ann Hematol. 2011 Apr 26. [Epub ahead of print]
	Analysis of carriers of hepatitis B virus from a tertiary referral hospital: Does the viral load change during the natural course of infection? Aakanksha, Asim M, Sharma PK, Das BC, Kar P. J Med Virol. 2011 Apr 22. doi: 10.1002/jmv.22074. [Epub ahead of print]
	HBV life cycle and novel drug targets Grimm D, Thimme R, Blum HE.AbstractHepatol Int. 2011 Mar 8. [Epub ahead of print]
	Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B Lampertico P, Viganò M, Facchetti F, Invernizzi F, Aroldi A, Lunghi G, Messa PG, Colombo M. Nephrol Dial Transplant. 2011 Apr 12. [Epub ahead of print]
	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized open-label study Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Hepatology. 2011 Apr 18. doi: 10.1002/hep.24361. [Epub ahead of print]
	Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Hepatol Int. 2011 Jan 5. [Epub ahead of print]
	The influence of hepatitis B and C virus infections on patient and allograft outcomes in kidney transplantation Uyar M, Sahin S, Dheir H, Gurkan A.Transplant Proc. 2011 Apr;43(3):850-2.
	De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients Wang LC, Chen EQ, Cao J, Liu L, Zheng L, Li DJ, Xu L, Lei XZ, Liu C, Tang H. Hepatol Int. 2011 Jan 19. [Epub ahead of print]
	Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data --- United States Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Apr 8;60(13):410-3.
	Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Liver Transpl. 2011 Apr 1. doi: 10.1002/lt.22312. [Epub ahead of print]
	Antioxidant supplements for liver diseases Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Cochrane Database Syst Rev. 2011 Mar 16;3:CD007749.
	Insulin, glucose, and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, Tsai KS, Yu MW. Carcinogenesis. 2011 Apr 3. [Epub ahead of print]
	Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic review Zhao SS, Tang LH, Dai XH, Wang W, Zhou RR, Chen LZ, Fan XG. Virol J. 2011 Mar 9;8(1):111. [Epub ahead of print]
	Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection Elefsiniotis IS, Tsoumakas K, Papadakis M, Vlachos G, Saroglou G, Antsaklis A. Eur J Intern Med. 2011 Apr;22(2):182-6. Epub 2011 Jan 7.
	Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Psychosomatics. 2011 Mar-Apr;52(2):127-32.
	Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]
	Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients Torre F, Giannini EG, Basso M, Fazio V, Savarino V, Picciotto A. J Gastrointestin Liver Dis. 2011 Mar;20(1):47-50.
	Increasing burden of liver disease in patients with HIV infection Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Lancet. 2011 Apr 2;377(9772):1198-209.
	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease Gisbert JP, Chaparro M, Esteve M. Aliment Pharmacol Ther. 2011 Mar;33(6):619-33.
	Lamivudine treatment is associated with improved survival in fulminant hepatitis B Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Liver Int. 2011 Apr;31(4):499-506.
	Liver transplant and chronic hepatitis B virus infection Selcuk H, Karakayali H, Haberal M. Exp Clin Transplant. 2011 Apr;9(2):94-7.
	Long-term results of hepatitis B immunoglobulin and lamuvidine for hepatitis B prophylaxis after liver transplantation Sevmis S, Aktas S, Zia HH, Atiq A, Akbas E, Selcuk H, Karakayali H, Haberal M. Transplant Proc. 2011 Mar;43(2):598-600.
	Response to hepatitis B vaccine differs by birthweight among neonates Cekmez F, Canpolat FE, Erdinç K, Cetinkaya M, Ak?n O, Pamuk U, Sar?c? SU. Vaccine. 2011 Mar 5. [Epub ahead of print]
	Pathogenesis of occult chronic hepatitis B virus infection de la Fuente RA, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodriguez C, Lledó JL, Castellano G. World J Gastroenterol. 2011 Mar 28;17(12):1543-8.
	Management of occult hepatitis B virus infection: An update for the clinician Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. World J Gastroenterol. 2011 Mar 28;17(12):1563-8.
	Diagnostic strategy for occult hepatitis B virus infection Ocana S, Casas ML, Buhigas I, Lledo JL. World J Gastroenterol. 2011 Mar 28;17(12):1553-7.
	Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Eur J Intern Med. 2011 Apr;22(2):187-90. Epub 2011 Jan 14.
	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Hepatol Res. 2011 Mar 21. doi: 10.1111/j.1872-034X.2011.00785.x. [Epub ahead of print]
	Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Transpl Int. 2011 Mar 15. doi: 10.1111/j.1432-2277.2011.01236.x. [Epub ahead of print]
	Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation D Avola D, Herrero JI. Rev Esp Enferm Dig. 2011 Mar;103(3):142-149.
	Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on Hwang S, Ahn CS, Song GW, Kim KH, Moon DB, Oh HB, Lim YS, Lee HC, Ha TY, Jung DH, Chung YH, Lee SG. Liver Transpl. 2011 Apr;17(4):456-65. doi: 10.1002/lt.22226.
	An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening Leung C, Tsoi E, Burns G, Sievert W. Oncologist. 2011 Apr 4. [Epub ahead of print]
	Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C. Antivir Ther. 2011;16(2):199-205.
	A Prospective Study of Hepatitis B Vaccination - A Comparison of Responders versus Nonresponders Brown CM, Donlon S, O'Kelly P, Casey AM, Collier C, Conlon PJ, Walshe JJ. Ren Fail. 2011;33(3):276-9.
	Student vaccination requirements of u.s. Health professional schools: a survey Lindley MC, Lorick SA, Spinner JR, Krull AR, Mootrey GT, Ahmed F, Myers R, Bednash GP, Cymet TC, Maeshiro R, Raines CF, Shannon SC, Sondheimer HM, Strikas RA. Ann Intern Med. 2011 Mar 15;154(6):391-400.
	Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Vaccine. 2011 Apr 4. [Epub ahead of print]
	Hepatitis B vaccination during pregnancy for preventing infant infection Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Cochrane Database Syst Rev. 2011 Mar 16;3:CD007879.
	Prevalence of Hepatitis B Surface Antigen in US-Born and Foreign-Born Asian/Pacific Islander College Students Quang YN, Vu J, Yuk J, Li CS, Chen M, Bowlus CL. J Am Coll Health. 2010 Jul-Aug;59(1):37-41.
	Hepatitis B virus genotyping: current methods and clinical implications Guirgis BS, Abbas RO, Azzazy HM. Int J Infect Dis. 2010 Jul 29. [Epub ahead of print]
	Chronic Hepatitis B: Who and How to Treat Landreneau SW, Herrera JL. PRACTICAL GASTROENTEROLOGY • NOVEMBER 2007;31:25-40.
	Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Gut Liver. 2010 Jun;4(2):212-8. Epub 2010 Jun 16.
	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Liver Int. 2010 Jun 15. [Epub ahead of print]
	Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons Colombo M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S298-301.
	On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective Chien RN. J Gastroenterol Hepatol. 2010 May;25(5):852-7.
	Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis Shi Z, Yang Y, Ma L, Li X, Schreiber A. Obstet Gynecol. 2010 Jul;116(1):147-59.
	Chronic Viral Infections and Invasive Procedures: Risk of Vertical Transmission and Current Recommendations López M, Coll O. Fetal Diagn Ther. 2010 Jun 19. [Epub ahead of print]
	Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M. J Hepatol. 2010 Mar 24. [Epub ahead of print]
	Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Avelino-Silva VI, D Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, de Brito Neves A, Abdala E. Clin Transplant. 2010 Apr 28. [Epub ahead of print]
	Hepatitis B virus infection and liver transplantation Kennedy M, Alexopoulos SP. Curr Opin Organ Transplant. 2010 May 4. [Epub ahead of print]
	Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Clin Biochem. 2010 Apr 27. [Epub ahead of print]
	Viral resistance in hepatitis B: prevalence and management Poordad F, Chee GM. Curr Gastroenterol Rep. 2010 Feb;12(1):62-9.
	HBV replication is significantly reduced by IL-6 Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, Chen ML, Chang C. J Biomed Sci. 2009 Apr 20;16:41.
	Toward elimination and eradication of hepatitis B Chen DS. J Gastroenterol Hepatol. 2010 Jan;25(1):19-25
	Hepatitis B and hepatocellular carcinoma Di Bisceglie A. Hepatology 2009;49(S6):S56-60)
	Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health 2010[Epub ahead of print]
	Epdemiology of hepatitis B in the United States Kim RW. Hepatology 2009;49:S28-S34
	The natural history of chronic hepatitis B virus infection McMahon B. Hepatology 2009;49(S6):S46-S55
	NIH Consensus Development Conference Statement on Management of Hepatitis B October 20-22, 2008
	End points of therapy in chronic hepatitis B Si Ahmed SN, Ecochard M, Zoulim F. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):37-49
	Evaluation of the patient with hepatitis B Rotman Y, Brown TA, Hoofnagle JH. Hepatology 2009;49(S5):S22-S27
	Special populations with hepatitis B virus infection Peters MG. Hepatology 2009;49(S5):S146-S155
	Hepatitis B: Reflections on the current approach to antiviral therapy Zoulim F, Perrillo R. J Hepatol 2008;48:S2-S19.
	Past HBV Viral Load as a Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study G. Chen et al. Am J Gastroenterol 2006; 101: 1797-1803
	Notes from the NIH on Hepatitis B... Dr. Jay Hoofnagle, Director, Liver Disease Research Branch NIDDK, National Institutes of Health, Bethesda, MD notes that today there are